Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT02535364 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

82

Enrollment

INDUSTRY

Sponsor class

Stopped Safety reasons

Conditions

Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: JCAR015 (CD19-targeted CAR T cells)

Sponsor

Juno Therapeutics, a Subsidiary of Celgene